• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

IDDS Vice President of Business Development Chairs Nasal Drug Delivery Symposium

Posted on: Friday, 22 July 2005, 09:01 CDT

Michael Sheckler, Vice President of Business Development for Intrac, Inc. (OTCBB: ITRD.OB) and its wholly-owned subsidiary Innovative Drug Delivery Systems (IDDS), was invited to chair the first Pharmaceutical Education Association's Nasal Drug Delivery Conference from July 25-27, 2005 at The Four Points Sheraton Hotel in Washington, D.C. Mr. Sheckler will also present a talk entitled, "Nasal Delivery of Analgesic Drugs". This talk will reflect the growing market for nasally delivered products including the Intrac/IDDS portfolio. This educational symposium will focus on the regulation, formulation and delivery system advances in nasal drug delivery.

The approximately 60 attendees at this inaugural conference will have the opportunity to hear over a dozen other speakers including Wallace P. Adams, Ph.D., from the office of Pharmaceutical Science, Center for Drug Evaluation and Research, US FDA; William Banks, M.D., from the Department of Internal Medicine, Geriatric Division, St. Louis University; Illana Gozes, Ph.D., of the Sackler Faculty of Medicine at Tel Aviv University and CSO at Allon Therapeutics; and Ajay Prasad, Ph.D., from the University of Delaware. Topics include bypassing the blood-brain barrier, to understanding dynamic airflow within the nasal passage, to enhancing nasal drugs' effectiveness by administering them in dry powder form. For additional information regarding this conference please visit www.pharmedassociates.com/drug.asp#p210.

About IDDS

IDDS is a specialty pharmaceutical company, applying innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information please visit our website: www.idds.com.

This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our ability to obtain working capital, our ability to successfully develop and commercialize drug candidates, and competition from other pharmaceutical companies.

Source: Business Wire

More News in this Category